Jazz Pharmaceuticals plc (JAZZ)

140.60 +3.15 (+2.29%) As of 01:41PM EDT. Market open.

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin 4
Ireland
353 1 634 7800
https://www.jazzpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3,200

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Bruce C. Cozadd	Co-Founder, Chairman & CEO	2.27M	2.63M	1964
Mr. Daniel N. Swisher Jr.	Pres & COO	1.27M	N/A	1963
Ms. Renee D. Gala	Exec. VP & CFO	1.03M	N/A	1972
Dr. Robert Iannone M.D.	Exec. VP and Global Head of R&D	983.25k	N/A	1967
Ms. Patricia Carr	Sr. VP & Chief Accounting Officer	N/A	N/A	1971
Dr. Finbar Larkin Ph.D.	Sr. VP of Technical Operations	N/A	N/A	1958
Ms. Andrea N. Flynn Ph.D.	VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Neena M. Patil J.D.	Exec. VP & Chief Legal Officer	N/A	N/A	1975
Dr. George Christopher Eliades Ph.D.	Sr. VP of Corp. Devel. & Chief Transformation Officer	N/A	N/A	1971
Ms. Heidi Manna	Sr. VP & Chief HR Officer	N/A	N/A	1972

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Corporate governance

Jazz Pharmaceuticals plc’s ISS governance QualityScore as of 1 February 2023 is 4. The pillar scores are Audit: 7; Board: 3; Shareholder rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.